Immunotherapeutic effects of recombinant Bacillus Calmette–Guérin containing sic gene in ex vivo and in vivo bladder cancer models

This is the authors' abstract. We don't add key points for this paper.

PURPOSE: and compared its effectiveness with that of BCG. MATERIALS AND METHODS: in terms of cell viability, cell migration, and cytokine concentrations. Using an orthotopic mouse model, we evaluated its anticancer effect and toxicity via bioluminescence imaging. RESULTS: 30MOI group than in the BCG 30MOI group after 10 days of treatment (p<0.05). CONCLUSIONS: is a useful tool for overcoming BCG unresponsiveness in non-muscle invasive bladder cancer. Additionally, high-throughput BCOC with a microfluidic system can successfully reflect the bladder cancer microenvironment.